Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02101853 · OUTCOME

Safety of Rapid Taper of Immune Suppression for Subset of HSCT Patients With MRD >= 0.01% Pre- and/or Post-HSCT With no aGVHD Defined as < 5% Rate of Treatment-related Mortality (TRM)

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia · Source last updated 2026-07-29

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 10 years

What was measured

The observed rate of TRM among this subset will be calculated with 95% confidence intervals and compared descriptively to target rate.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denom Units Selected
Participants
description
The observed rate of TRM among this subset will be calculated with 95% confidence intervals and compared descriptively to target rate.
reporting Status
NOT_POSTED
time Frame
Up to 10 years
title
Safety of Rapid Taper of Immune Suppression for Subset of HSCT Patients With MRD >= 0.01% Pre- and/or Post-HSCT With no aGVHD Defined as < 5% Rate of Treatment-related Mortality (TRM)
type
OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice